United States v. Aegerion Pharmaceuticals, Inc.

MEMORANDUM & ORDER

WILLIAM G. YOUNG, DISTRICT JUDGE

Let’s see if I’ve got this straight.1

Aegerion Pharmaceuticals, Iric. (“Aeger-ion”) developed an effective medicine, called Juxtapid, to treat high cholesterol in people with a rare genetic disease. The treatment did not come cheap. “At market launch in January 2013, Juxtapid cost roughly $295,000 per patient per year. The annual cost of Juxtapid later increased to over $330,000 per patient per year.” Infor-, mation, ¶ 19.

Thereafter Aegerion engaged in a series of unfair and deceptive acts, including outright fraud, which pervaded corporate…